Monitor litigation discovery outcomes—if the company identifies responsible parties, it could trigger regulatory scrutiny and short covering. The defense contract (undisclosed value) and partnership consortium may lead to further government awards. Stock likely to be volatile on legal developments.
Price Chart
Executive Summary
Lunai Bioworks issued a CEO letter updating on a first revenue-generating defense contract (undisclosed value), a Phase I/II STTR grant of $1.85M to collaborator BioSymetrics, and a lawsuit against unidentified parties for alleged naked short selling, for which the court granted expedited discovery. The company also confirmed Nasdaq listing compliance. No financial results were disclosed.
Key Facts
- Secured first revenue-generating multi-year defense collaboration with BioSymetrics for chemical threat assessment (value not disclosed)
- Pathfinder Consortium established with Harvard, Brigham and Women's Hospital, University of Utah, Purdue, University of Colorado
- Phase I/II STTR grant of $1.85 million awarded to BioSymetrics for alcohol use disorder research
- Filed lawsuit in Delaware for naked short selling; court found good cause for expedited discovery; 29.6 million failing-to-deliver shares (81.6% of outstanding) alleged, with peak volume of 554 million shares on March 17, 2026
- Achieved compliance with Nasdaq listing requirements
Financial Impact
No revenue or earnings data disclosed. Only quantified financial element is a $1.85M STTR grant to collaborator BioSymetrics. Contract value of defense collaboration is undisclosed.
Risk Factors
- Litigation may not succeed or may be dismissed; expedited discovery does not guarantee a favorable outcome
- Defense contract and neurology pipeline are at early stages; no meaningful revenue visibility
- Micro-cap with $13M market cap; high volatility and low liquidity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-000871 |
| Document: e7731_ex99-1.htm | 0001731122-26-000871 |
| Document: 0001731122-26-000871-index-headers.html | 0001731122-26-000871 |
| Document: 0001731122-26-000871-index.html | 0001731122-26-000871 |
| Document: 0001731122-26-000871.txt | 0001731122-26-000871 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.2946 $0.2750 | ▲ +6.65% | ▲ +7.36% | $0.2750 (+6.65%) |
Oct 15, 2026 11d ago | SC 13D/A | $0.6800 $0.4720 | ▲ +30.59% | ▲ +31.01% | $0.2750 (+59.56%) |
Oct 9, 2026 17d ago | 8-K | $1.23 $1.11 | ▲ +9.76% | ▲ +9.70% | $0.2750 (+77.64%) |
Sep 29, 2026 27d ago | NT 10-K | $1.47 $1.38 | ▲ +6.12% | ▲ +6.30% | $0.2750 (+81.29%) |
Jun 17, 2026 18w ago | 8-K | $3.78 $4.15 | ▲ +9.79% | ▲ +10.10% | $0.2750 (−92.72%) |
Jun 16, 2026 18w ago | 8-K | $4.00 $3.78 | ▼ −5.50% | ▼ −6.28% | $0.2750 (−93.12%) |
May 20, 2026 22w ago | 8-K | $1.80 $2.32 | ▼ −28.89% | ▼ −28.69% | $0.2750 (+84.72%) |
May 1, 2026 25w ago | 8-K | $2.60 $2.50 | ▼ −3.88% | ▼ −4.68% | $0.2750 (−89.41%) |
Apr 28, 2026 25w ago | DEFA14A | $2.66 $2.64 | ▼ −0.90% | ▼ −1.92% | $0.2750 (−89.68%) |
Mar 5, 2026 33w ago | 8-K | $1.86 $1.76 | ▲ +5.25% | ▲ +6.10% | $0.2750 (+85.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers